Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 이용희 | - |
dc.date.accessioned | 2016-08-28T11:08:23Z | - |
dc.date.available | 2016-08-28T11:08:23Z | - |
dc.date.issued | 2005 | - |
dc.identifier.issn | 0195-668X | - |
dc.identifier.other | OAK-12783 | - |
dc.identifier.uri | https://dspace.ewha.ac.kr/handle/2015.oak/228855 | - |
dc.description.abstract | Aims: We have previously reported that lower doses of hormone therapy (L-HT) and tibolone have different effects on markers of cardiovascular disease when compared with conventional doses of HT. The objective was to compare the effects of L-HT and tibolone on lipid profile, vasodilation, and factors associated with inflammation and haemostasis. Methods and results: Forty-one women received a combination of micronized progesterone 100 mg with conjugated equine estrogen 0.3 mg vs. tibolone 2.5 mg alone daily in random order during 2 months with 2 months washout period. When compared with L-HT, tibolone significantly reduced total cholesterol (P < 0.001), triglyceride (P < 0.001), HDL cholesterol (P < 0.001) levels, and triglyceride/HDL cholesterol ratios (P = 0.004) except total cholesterol/HDL cholesterol ratios. Tibolone improved flow-mediated response to hyperaemia from baseline values (P < 0.001) by a similar magnitude to L-HT. L-HT and tibolone did not increase high-sensitivity C-reactive protein relative to baseline values. L-HT reduced antithrombin III from baseline values (P = 0.037), compared with tibolone showing no changes. However, there was no difference between either. In contrast, tibolone increased pro-thrombin fragment 1+2 (F1 + 2) from baseline values (P = 0.002), compared with L-HTshowing no changes. Tibolone significantly reduced plasma plasminogen activator inhibitor type 1 (PAI-1) antigen levels from baseline values (P = 0.004), compared with L-HTshowing no changes. The effects of L-HT and tibolone on F1+2 and PAI-1 were significantly different (P = 0.045 and P = 0.008, respectively). Conclusion: Both tibolone and L-HT improved flow-mediated response by a similar magnitude and did not significantly increase high-sensitivity C-reactive protein. However, tibolone significantly reduced PAI-1, but increased F1+2 more than L-HT. © The European Society of Cardiology 2005. All rights reserved. | - |
dc.language | English | - |
dc.title | Significant differential effects of lower doses of hormone therapy or tibolone on markers of cardiovascular disease in post-menopausal women: A randomized, double-blind, crossover study | - |
dc.type | Article | - |
dc.relation.issue | 14 | - |
dc.relation.volume | 26 | - |
dc.relation.index | SCI | - |
dc.relation.index | SCIE | - |
dc.relation.index | SCOPUS | - |
dc.relation.startpage | 1362 | - |
dc.relation.lastpage | 1368 | - |
dc.relation.journaltitle | European Heart Journal | - |
dc.identifier.doi | 10.1093/eurheartj/ehi311 | - |
dc.identifier.wosid | WOS:000230780900007 | - |
dc.identifier.scopusid | 2-s2.0-25444448995 | - |
dc.author.google | Kwang K.K. | - |
dc.author.google | Seung H.H. | - |
dc.author.google | Shin M.-S. | - |
dc.author.google | Jeong Y.A. | - |
dc.author.google | Lee Y. | - |
dc.author.google | Eak K.S. | - |
dc.contributor.scopusid | 이용희(35737417000) | - |
dc.date.modifydate | 20211210153745 | - |